The Journal of Pediatrics
Volume 151, Issue 1 , Pages 34-42.e1 , July 2007

Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing

  • Eric A.F. Simoes, MB, BS, DCH, MD

      Affiliations

    • Department of Pediatric Infectious Diseases, University Of Colorado School Of Medicine and The Children’s Hospital, Denver, CO
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • Corresponding Author InformationReprint requests: Eric A. F. Simoes, MD, DCH, The Children’s Hospital, 1056 E 19th Ave, B070, Denver, CO 80218.
    • ,
  • Jessie R. Groothuis, MD

      Affiliations

    • Abbott Laboratories, Inc, Chicago, IL
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • Dr Groothuis currently is Vice President, Medical and Scientific Affairs and Head, Infectious Diseases and Vaccines, MedImmune, Inc.
    • ,
  • Xavier Carbonell-Estrany, MD, PhD

      Affiliations

    • Neonatology Service, Hospital Clinic, Institute and Clinic of Gynecology, Obstetrics and Neonatology, Barcelona, Spain
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • ,
  • Christian H.L. Rieger, MD

      Affiliations

    • Department of Pediatrics, St Josef Hospital, Ruhr University, Bochum, Germany
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • ,
  • Ian Mitchell, MA, MB, ChB

      Affiliations

    • Institute of Maternal and Child Health, University of Calgary, Calgary, Alberta, Canada
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • ,
  • Linda M. Fredrick, MS

      Affiliations

    • Abbott Laboratories, Abbott Park, IL
    • Linda Fredrick currently is an employee of Abbott Laboratories.
    • ,
  • Jan L.L. Kimpen, MD, PhD

      Affiliations

    • Department of Pediatrics, Wilhelmina Children’s Hospital, University Medical Center, Utrecht, The Netherlands.
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • ,
  • Palivizumab Long-Term Respiratory Outcomes Study Group

      Affiliations

    • The members of the Palivizumab Long-Term Respiratory Outcomes Study Group are listed in an appendix, available at www.jpeds.com.

Received 14 April 2006 ,Revised 28 December 2006 ,Accepted 8 February 2007.

References 

  1. Simoes EAF. Respiratory syncytial virus infections. Lancet. 1999;354:847–852
  2. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501–1507
  3. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171:137–141
  4. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541–545
  5. Bont L, Steijn M, Van Aalderen WM, Brus F, Th Draaisma JM, Van Diemen-Steenvoorde RA, et al. Seasonality of long-term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax. 2004;59:512–516
  6. Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005;16:386–392
  7. Korppi M, Piippo-Savolainen E, Korhonen K, Remes S. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 2004;38:155–160
  8. Shattuck KE, Abu-Ghosh AM, Wildin SR, Landry SH, Smith KE. Respiratory morbidity in three-year-old children born preterm. Neonatal Intensive Care. 1998;11:11–15
  9. Chan KN, Noble Jamieson CM, Elliman A, Bryan EM, Silverman M. Lung function in children of low birth weight. Arch Dis Child. 1989;64:1284–1293
  10. Mai XM, Gaddlin PO, Nilsson L, Finnstrom O, Bjorksten B, Jenmalm MC, et al. Asthma, lung function and allergy in 12-year-old children with very low birth weight: a prospective study. Pediatr Allergy Immunol. 2003;14:184–192
  11. Groothuis JR, Simoes EAF, Levin MJ, Rodriguez WJ, Hall CB, Meissner HC, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524–1530
  12. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93–99
  13. Wenzel SE, Gibbs RL, Lehr MV, Simoes EAF. Respiratory outcomes in high-risk children 7-10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med. 2002;112:627–633
  14. The IMpact Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537
  15. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22:823–827
  16. Simoes EAF, Hayward AR, Ponnuraj EM, Straumanis JP, Stenmark KR, Wilson HL, et al. Respiratory syncytial virus infects the Bonnet monkey, Macaca radiata. Pediatr Dev Pathol. 1999;2:316–326
  17. Mandy FF, Perelmutter L. Laboratory measurement of total human serum IgE. J Clin Immunoassay. 1983;2:140–146
  18. Trefny P, Stricker T, Baerlocher C, Sennhauser FH. Family history of atopy and clinical course of RSV infection in ambulatory and hospitalized infants. Pediatr Pulmonol. 2000;30:302–306
  19. Noble V, Murray M, Webb MS, Alexander J, Swarbrick AS, Milner AD. Respiratory status and allergy 9 to 10 years after acute bronchiolitis. Arch Dis Child. 1997;76:315–319
  20. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. N Engl J Med. 1995;332:133–138
  21. Saez-Llorens X, Moreno MT, Ramilo O, Sanchez PJ, Top FH, Connor EM, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23:707–712
  22. American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: indication for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211–1216
  23. Carbonell Estrany X, Quero Jimenez J Board of Directors of the Spanish Society of Neonatology. Recommendations for the prevention of respiratory syncytial virus infections (Standards Committee of the Spanish Society of Neonatology). Ann Esp Pediatr. 2000;52:372–374
  24. Ball TM, Castro-Rodriguez JA, Griffith KA, Holberg CJ, Martinez FD, Wright AL. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med. 2000;343:538–543
  25. Culley FJ, Pollott J, Openshaw PJM. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in childhood. J Exp Med. 2002;196:381–386
  26. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma JT, et al. Peripheral blood cytokine responses and disease severity in respiratory syncytial virus bronchiolitis. Eur Respir J. 1999;14:144–149
  27. Welliver RC, Garofalo RP, Ogra PL. Beta-chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infection. Pediatr Infect Dis J. 2002;21:457–461
  28. Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Holt PG. Development of allergen-specific T-cell memory in atopic and normal children. Lancet. 1999;353:196–200
  29. Holt PG, Upham JW, Sly PD. Contemporaneous maturation of immunologic and respiratory functions during early childhood: implications for development of asthma prevention strategies. J Allergy Clin Immunol. 2005;116:16–24
  30. Holt PG, Sly PD. Interactions between respiratory tract infections and atopy in the aetiology of asthma. Eur Respir J. 2002;19:538–545
  31. Piedimonte G. What causes allergy and asthma? (Early postnatal influences). Pediatr Pulmonol Suppl. 2004;26:208–210
  32. Hu C, Wedde-Beer K, Auais A, Rodriguez MM, Piedimonte G. Nerve growth factor and nerve growth factor receptors in respiratory syncytial virus-infected lungs. Am J Physiol Lung Cell Mol Physiol. 2002;283:L494–L502
  33. Lemanske RF, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. J Allergy Clin Immunol. 2005;116:571–577

 This study was funded by grants from Abbott Laboratories to the individual investigators. The study sponsors collaborated on study design, managed data collection, and performed data analysis.

PII: S0022-3476(07)00161-8

doi: 10.1016/j.jpeds.2007.02.032

The Journal of Pediatrics
Volume 151, Issue 1 , Pages 34-42.e1 , July 2007

Article Tools

* Image Usage & Resolution